• Mira Pharmaceuticals highlighted Ketamir-2, an oral selective NMDA receptor modulator being developed for chemotherapy-induced peripheral neuropathy, a condition it estimates affects 30%-40% of chemotherapy patients with no FDA-approved treatments.
• Phase 1 program completed in 56 healthy volunteers with 0 serious adverse events, testing doses up to 600 mg.
• Phase 2a protocol submission targeted for H1 2026 under an active IND, with enrollment expected to begin in 2026 and first readout expected in Q1 2027.
• Planned Phase 2a design calls for a randomized, double-blind, placebo-controlled, three-period crossover study in 24 patients, evaluating 150 mg and 300 mg oral doses.
• Estimated all-in cost for Phase 2a cited at USD 4-6 million, with management describing the company as debt-free.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mira Pharmaceuticals Inc. published the original content used to generate this news brief on May 13, 2026, and is solely responsible for the information contained therein.